Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis

Allon Friedman, A. G. Bostom, A. S. Levey, I. H. Rosenberg, J. Selhub, A. Pierratos

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Mild hyperhomocysteinemia, a putative risk factor for arteriosclerotic outcomes, is seen in >85% of hemodialysis patients. Therapeutic strategies, including pharmacologic-dose B vitamin supplementation and "high-flux" or "super-flux" hemodialysis, have consistently failed to normalize total homocysteine (tHcy) levels in these patients. Predialysis plasma tHcy levels in 23 patients who were undergoing nocturnal hemodialysis (NHD) six or seven nights/wk were compared with those in 31 patients from the same Canadian dialysis unit who were undergoing chronic standard hemodialysis (SHD) (all 12 μM; NHD, 57%; SHD, 94%; P = 0.002). Analysis of covariance adjusted for plasma folate, vitamin B12, and pyridoxal 5′-phosphate levels, age, and gender confirmed that NHD was independently associated with 6.0 μM lower geometric mean tHcy levels (P = 0.001). It is concluded that tHcy levels are significantly lower among NHD patients, compared with SHD patients. Clinical trials will be necessary to confirm that NHD is effective in reducing tHcy levels among patients with dialysis-dependent end-stage renal disease.

Original languageEnglish (US)
Pages (from-to)265-268
Number of pages4
JournalJournal of the American Society of Nephrology
Volume13
Issue number1
StatePublished - 2002
Externally publishedYes

Fingerprint

Homocysteine
Renal Dialysis
Dialysis
Vitamin B Complex
Hyperhomocysteinemia
Pyridoxal Phosphate
Vitamin B 12
Folic Acid
Chronic Kidney Failure
Clinical Trials

ASJC Scopus subject areas

  • Nephrology

Cite this

Friedman, A., Bostom, A. G., Levey, A. S., Rosenberg, I. H., Selhub, J., & Pierratos, A. (2002). Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. Journal of the American Society of Nephrology, 13(1), 265-268.

Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. / Friedman, Allon; Bostom, A. G.; Levey, A. S.; Rosenberg, I. H.; Selhub, J.; Pierratos, A.

In: Journal of the American Society of Nephrology, Vol. 13, No. 1, 2002, p. 265-268.

Research output: Contribution to journalArticle

Friedman, A, Bostom, AG, Levey, AS, Rosenberg, IH, Selhub, J & Pierratos, A 2002, 'Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis', Journal of the American Society of Nephrology, vol. 13, no. 1, pp. 265-268.
Friedman, Allon ; Bostom, A. G. ; Levey, A. S. ; Rosenberg, I. H. ; Selhub, J. ; Pierratos, A. / Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. In: Journal of the American Society of Nephrology. 2002 ; Vol. 13, No. 1. pp. 265-268.
@article{5f158af647444716bdfffacba882bb62,
title = "Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis",
abstract = "Mild hyperhomocysteinemia, a putative risk factor for arteriosclerotic outcomes, is seen in >85{\%} of hemodialysis patients. Therapeutic strategies, including pharmacologic-dose B vitamin supplementation and {"}high-flux{"} or {"}super-flux{"} hemodialysis, have consistently failed to normalize total homocysteine (tHcy) levels in these patients. Predialysis plasma tHcy levels in 23 patients who were undergoing nocturnal hemodialysis (NHD) six or seven nights/wk were compared with those in 31 patients from the same Canadian dialysis unit who were undergoing chronic standard hemodialysis (SHD) (all 12 μM; NHD, 57{\%}; SHD, 94{\%}; P = 0.002). Analysis of covariance adjusted for plasma folate, vitamin B12, and pyridoxal 5′-phosphate levels, age, and gender confirmed that NHD was independently associated with 6.0 μM lower geometric mean tHcy levels (P = 0.001). It is concluded that tHcy levels are significantly lower among NHD patients, compared with SHD patients. Clinical trials will be necessary to confirm that NHD is effective in reducing tHcy levels among patients with dialysis-dependent end-stage renal disease.",
author = "Allon Friedman and Bostom, {A. G.} and Levey, {A. S.} and Rosenberg, {I. H.} and J. Selhub and A. Pierratos",
year = "2002",
language = "English (US)",
volume = "13",
pages = "265--268",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis

AU - Friedman, Allon

AU - Bostom, A. G.

AU - Levey, A. S.

AU - Rosenberg, I. H.

AU - Selhub, J.

AU - Pierratos, A.

PY - 2002

Y1 - 2002

N2 - Mild hyperhomocysteinemia, a putative risk factor for arteriosclerotic outcomes, is seen in >85% of hemodialysis patients. Therapeutic strategies, including pharmacologic-dose B vitamin supplementation and "high-flux" or "super-flux" hemodialysis, have consistently failed to normalize total homocysteine (tHcy) levels in these patients. Predialysis plasma tHcy levels in 23 patients who were undergoing nocturnal hemodialysis (NHD) six or seven nights/wk were compared with those in 31 patients from the same Canadian dialysis unit who were undergoing chronic standard hemodialysis (SHD) (all 12 μM; NHD, 57%; SHD, 94%; P = 0.002). Analysis of covariance adjusted for plasma folate, vitamin B12, and pyridoxal 5′-phosphate levels, age, and gender confirmed that NHD was independently associated with 6.0 μM lower geometric mean tHcy levels (P = 0.001). It is concluded that tHcy levels are significantly lower among NHD patients, compared with SHD patients. Clinical trials will be necessary to confirm that NHD is effective in reducing tHcy levels among patients with dialysis-dependent end-stage renal disease.

AB - Mild hyperhomocysteinemia, a putative risk factor for arteriosclerotic outcomes, is seen in >85% of hemodialysis patients. Therapeutic strategies, including pharmacologic-dose B vitamin supplementation and "high-flux" or "super-flux" hemodialysis, have consistently failed to normalize total homocysteine (tHcy) levels in these patients. Predialysis plasma tHcy levels in 23 patients who were undergoing nocturnal hemodialysis (NHD) six or seven nights/wk were compared with those in 31 patients from the same Canadian dialysis unit who were undergoing chronic standard hemodialysis (SHD) (all 12 μM; NHD, 57%; SHD, 94%; P = 0.002). Analysis of covariance adjusted for plasma folate, vitamin B12, and pyridoxal 5′-phosphate levels, age, and gender confirmed that NHD was independently associated with 6.0 μM lower geometric mean tHcy levels (P = 0.001). It is concluded that tHcy levels are significantly lower among NHD patients, compared with SHD patients. Clinical trials will be necessary to confirm that NHD is effective in reducing tHcy levels among patients with dialysis-dependent end-stage renal disease.

UR - http://www.scopus.com/inward/record.url?scp=0036137819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036137819&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 265

EP - 268

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 1

ER -